Loading News...
Volver al Panel
Amgen Inc. logo

Amgen Inc. (AMGN)

Valores intradiarios en tiempo real

Resumen del Mercado

From:
To:
AMGN Intraday
No data available
SímboloAMGN
Fecha de SalidaJun 17, 1983
CEOMr. Robert A. Bradway
Empleados a Tiempo Completo31.5k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Rendimiento
PeríodoRentabilidad %Cambio de Valor
1 Día
+1.16%
+4.70 US$
5 Días
+6.51%
+25.10 US$
1 Mes
-6.72%
-29.59 US$
6 Meses
+17.77%
+61.98 US$

Analizando el Mercado con IA

Evaluando los últimos 30 días de historial y métricas fundamentales de AMGN...

Estadísticas Clave
Cap. de Mercado
222.15B
Relación P/E
25.49
Rend. de Div.
2.48%
Máx. 52 Semanas
$447.03
Mín. 52 Semanas
$269.77

Consenso de Analistas

CONSENSOMantener
ALCISTA1235.3%
NEUTRAL1750.0%
BAJISTA514.7%

Objetivos de Precios de Analistas a 52 Semanas

Objetivo Mín.
$225.00
Objetivo Máx.
$457.00
Actual$410.75
Objetivo Prom.$389.22

Recomendaciones de Analistas

Precio Objetivo:$389.22($225.00 - $457.00)
FirmaCalificaciónPrecio ObjetivoPotencial de AlzaFecha
HSBCHold$425.00+3.47%10/9/2026
BMO CapitalMarket Perform$450.00+9.56%8/9/2026
Cantor FitzgeraldNeutral$400.00-2.62%8/9/2026
Wells FargoEqual-Weight$435.00+5.91%4/9/2026
Piper SandlerOverweight$457.00+11.26%20/8/2026
Morgan StanleyEqual-Weight$362.00-11.87%19/8/2026
Argus ResearchBuy$460.00+11.99%19/8/2026
MizuhoNeutral$352.00-14.30%18/8/2026
Cantor FitzgeraldNeutral$400.00-2.62%18/8/2026
BarclaysEqual-Weight$380.00-7.49%14/8/2026
Pensamientos de la Comunidad

Comparta su análisis y sentimiento sobre AMGN

Únase a la comunidad para compartir su análisis